Decoy Therapeutics
DCOY
4 hedge funds and large institutions have $98.6M invested in Decoy Therapeutics in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $111M → $98.6M (-$12.3M)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Soros Fund Management
New York
|
-$588K |
| 2 |
D.E. Shaw & Co
New York
|
-$586K |
| 3 |
SIM
Spark Investment Management
New York
|
-$439K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$349K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$267K |
DCOY Hedge Fund Activity: Q2 2015 in Review
4 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2015, worth a combined $98.6M — down 11% from $111M a quarter earlier.
Fund positioning in DCOY was balanced in Q2 2015: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Soros Fund Management, cutting an estimated $588K.
- 4 institutional investors held Decoy Therapeutics (DCOY) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $98.6M of Decoy Therapeutics stock for Q2 2015, down 11% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q2 2015 and 0 closed out.
- The largest Decoy Therapeutics seller in Q2 2015 was Soros Fund Management, an estimated $588K sold.
Based on aggregated 13F filings for Q2 2015.